rxtimes.com
News | Rx Times Pharmacy Magazine
http://rxtimes.com/news
Statement of Fresenius Medical Care North America Regarding Centers for Medicare and Medicaid Services Request for Information. FDA Approves TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain. FDA Approves TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain. Subscribe to our email newsletter. PHARMACY...
rxtimes.com
Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study | Rx Times Pharmacy Magazine
http://rxtimes.com/oramed-enrolls-first-patient-in-its-phase-iib-oral-insulin-study
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Oramed CEO,...
rxtimes.com
Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014, says GlobalData | Rx Times Pharmacy Magazine
http://rxtimes.com/global-gene-therapy-deals-sky-rocketed-to-nearly-5-billion-in-2014-says-globaldata
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. The company...
rxtimes.com
Novartis Pharmaceuticals launches first app for visually impaired | Rx Times Pharmacy Magazine
http://rxtimes.com/novartis-pharmaceuticals-launches-the-first-app-for-visually-impaired
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. 8220;With t...
rxtimes.com
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc. | Rx Times Pharmacy Magazine
http://rxtimes.com/novartis-deepens-its-industry-leading-pipeline-with-acquisition-of-spinifex-pharmaceuticals-inc
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Positive re...
rxtimes.com
Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy | Rx Times Pharmacy Magazine
http://rxtimes.com/isis-pharmaceuticals-reports-data-from-isis-smn-rx-in-children-with-spinal-muscular-atrophy
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. An analysis...
rxtimes.com
Featured | Rx Times Pharmacy Magazine
http://rxtimes.com/category/news/featured
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Up to $100,...
rxtimes.com
Toxics Reform Legislation Needs to be Strengthened | Rx Times Pharmacy Magazine
http://rxtimes.com/toxics-reform-legislation-needs-to-be-strengthened
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma. Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications. Fran Teplit...
rxtimes.com
Advertising | Rx Times Pharmacy Magazine
http://rxtimes.com/advertise
Reach Your Target Audience Effectively. RxTimes.com effectively reaches a large, loyal and growing audience of decision-making professionals by granting access, through a single site, to multiple voices. RxTimes endless store of industry articles leads to longer session times and increased impressions for the advertiser. For more information, please email info@rxtimes.com. Subscribe to our email newsletter. Connect with Rx Times.